Compugen Ltd. CGEN, announced today the discovery and initial
validation of two new drug target candidates for monoclonal antibody (mAb)
cancer therapy. These new candidates have been shown to be expressed in
multiple types of tumors and were shown to have an immunomodulatory activity
in affecting both innate and adaptive immune responses, thus providing the
potential for an efficient and targeted approach in cancer treatment. By
offering a different mode of action from Compugen's other immune checkpoint
candidates, these molecules further broaden the scope of the Company's
Pipeline Program for monoclonal antibody treatment of cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in